Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07582003 | Nov 2026 → Nov 2028 expected | adenoma, colorectal cancer | Jun Gong, MD | Not yet recruiting | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT00513461 | Oct 2007 → Aug 2012 | hepatitis C virus infection, liver cancer | Chao Family Comprehensive Cancer Center | Completed | Missed primary |
| Phase 2 | NCT00475176 | May 2007 → May 2011 | chronic hepatitis C virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00125281 | Jul 2005 → Jul 2007 | cirrhosis of liver | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | No outcome recorded |
| Phase 2 | NCT00093847 | May 2004 → Feb 2009 | depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT00573313 | Sep 2005 → Jun 2009 | alcoholic liver disease | University of California, Davis | Completed | Missed primary |
| Phase 3 | NCT00108589 | Jan 2004 → Dec 2006 | hepatitis | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05340634 | Apr 2020 → Feb 2022 | polycystic ovary syndrome | Margan Biotech | Completed | No outcome recorded |
| Phase not applicable4 trials · 1 met primary | ||||||
| — | NCT03932474 | Sep → Nov 2018 | depressive disorder | Nutrilinea srl | Completed | Met primary |
| — | NCT03178929 | Jul 2017 → Jul 2020 | liver cancer | Beijing Insight Science & Technology Co. Ltd. | Unknown | No outcome recorded |
| — | NCT02231333 | Jul 2013 → Jul 2015 | metabolic dysfunction-associated steatohepatitis | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT00694564 | Jun 2007 → Mar 2011 | — | Huang, Jeannie, M.D. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02586285 Comparator | Jun 2015 → Dec 2017 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-adenosylmethionine | “The use of S-adenosyl methionine (SAMe), a naturally occurring molecule that serves as a methyl donor in human cellular metabolism, as adjunctive treatment for antidepressant...” PMID 20595412 ↗ Jul 201012“SAMEUp, the investigational food supplement, is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU, already...” NCT03932474 ↗ “A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.” PMID 26130251 ↗ Jun 2015 “200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 mg vitamin B6” NCT05340634 ↗ |
| Known as | S-adenosyl-L-methionine | “We examined whether adjunctive S-adenosyl-l-methionine (SAMe) is associated with greater improvement in sexual functioning than adjunctive placebo by measuring changes in...” PMID 21398094 ↗ Mar 20112“Several literature findings suggest that an oral combination of the two food supplements SAMe (S-adenosyl-L-methionine) and probiotic Lactobacillus plantarum might be...” NCT03932474 ↗ “S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial.” PMID 22044287 ↗ Nov 2011 |
| Known as | SAMe | “The use of S-adenosyl methionine (SAMe), a naturally occurring molecule that serves as a methyl donor in human cellular metabolism, as adjunctive treatment for antidepressant...” PMID 20595412 ↗ Jul 20107“SAMEUp, the investigational food supplement, is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU, already...” NCT03932474 ↗ “S-Adenosylmethionine (SAMe) will be given at an oral daily dose of 1600-2400 mg daily divided into 400 mg tablets in the morning before breakfast and in the evening before...” NCT07582003 ↗ “In animal models of hepatocellular carcinoma (HCC), deficiency of S-adenosylmethionine (SAMe) increased the risk of HCC whereas administration of SAMe reduced HCC.” PMID 26130251 ↗ Jun 2015 “Alcoholic liver disease patients receiving S-adenosylmethionine (SAMe)at 400 mg capsule three times daily for 24 weeks” NCT00573313 ↗ “S-adenosyl methionine (SAMe) improves interferon signaling in cell culture.” PMID 20854821 ↗ Sep 2010 “S-adenosyl-methionine (SAMe) capsules” NCT00125281 ↗ “S-adenosylmethionine (SAMe)” NCT02231333 ↗ |
| Modality | Other / unclassified | “SAMe is a nutritional supplement” NCT00475176 ↗ |
| Route | Oral | “trial of adjunctive oral SAMe” PMID 20595412 ↗ Jul 2010 |
| Target | STAT1 | “SAMe increased induction of ISGs and the antiviral effects of interferon by increasing STAT1 methylation” PMID 20854821 ↗ Sep 2010 |